Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 126

1.

A nonsense mutant of the hepatitis B virus large S protein antagonizes multiple tumor suppressor pathways through c-Jun activation domain-binding protein1.

Chiu SY, Chung HJ, Chen YT, Huang MS, Huang CC, Huang SF, Matsuura I.

PLoS One. 2019 Mar 14;14(3):e0208665. doi: 10.1371/journal.pone.0208665. eCollection 2019.

2.

Somatic mutations of PREX2 gene in patients with hepatocellular carcinoma.

Yang MH, Yen CH, Chen YF, Fang CC, Li CH, Lee KJ, Lin YH, Weng CH, Liu TT, Huang SF, Teh BT, Chen YA.

Sci Rep. 2019 Feb 22;9(1):2552. doi: 10.1038/s41598-018-36810-5.

3.

A novel spontaneous hepatocellular carcinoma mouse model for studying T-cell exhaustion in the tumor microenvironment.

Liu YT, Tseng TC, Soong RS, Peng CY, Cheng YH, Huang SF, Chuang TH, Kao JH, Huang LR.

J Immunother Cancer. 2018 Dec 7;6(1):144. doi: 10.1186/s40425-018-0462-3.

4.

CBAP modulates Akt-dependent TSC2 phosphorylation to promote Rheb-mTORC1 signaling and growth of T-cell acute lymphoblastic leukemia.

Chiang YJ, Liao WT, Ho KC, Wang SH, Chen YG, Ho CL, Huang SF, Shih LY, Yang-Yen HF, Yen JJ.

Oncogene. 2019 Feb;38(9):1432-1447. doi: 10.1038/s41388-018-0507-6. Epub 2018 Sep 28.

5.

AAV serotype 8-mediated liver specific GNMT expression delays progression of hepatocellular carcinoma and prevents carbon tetrachloride-induced liver damage.

Fang CC, Wu CF, Liao YJ, Huang SF, Chen M, Chen YA.

Sci Rep. 2018 Sep 14;8(1):13802. doi: 10.1038/s41598-018-30800-3.

6.

Metabolic risk factors are associated with non-hepatitis B non-hepatitis C hepatocellular carcinoma in Taiwan, an endemic area of chronic hepatitis B.

Huang SF, Chang IC, Hong CC, Yen TC, Chen CL, Wu CC, Tsai CC, Ho MC, Lee WC, Yu HC, Shen YY, Eng HL, Wang J, Tseng HH, Jeng YM, Yeh CT, Chen CL, Chen PJ, Liaw YF.

Hepatol Commun. 2018 Apr 18;2(6):747-759. doi: 10.1002/hep4.1182. eCollection 2018 Jun.

7.

Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan.

Surveillance group; Diagnosis group; Staging group; Surgery group; Local ablation group; TACE/TARE/HAI group; Target therapy/systemic therapy group; Radiotherapy group; Prevention group; Drafting group.

J Formos Med Assoc. 2018 May;117(5):381-403. doi: 10.1016/j.jfma.2017.09.007. Epub 2017 Oct 24.

8.

Upregulation of CISD2 augments ROS homeostasis and contributes to tumorigenesis and poor prognosis of lung adenocarcinoma.

Li SM, Chen CH, Chen YW, Yen YC, Fang WT, Tsai FY, Chang JL, Shen YY, Huang SF, Chuu CP, Chang IS, Hsiung CA, Jiang SS.

Sci Rep. 2017 Sep 19;7(1):11893. doi: 10.1038/s41598-017-12131-x.

9.

Characterization of a new murine cell line of sarcomatoid hepatocellular carcinoma and its application for biomarker/therapy development.

Yen CH, Lai CC, Liao CC, Wang SF, Liao YJ, Tung CY, Hung JH, Huang SF, Chen YA.

Sci Rep. 2017 Jun 8;7(1):3052. doi: 10.1038/s41598-017-03164-3.

10.

Overexpression of MutL homolog 1 and MutS homolog 2 proteins have reversed prognostic implications for stage I-II colon cancer patients.

Huang SC, Huang SF, Chen YT, Chang Y, Chiu YT, Chang IC, Wu HI, Chen JS.

Biomed J. 2017 Feb;40(1):39-48. doi: 10.1016/j.bj.2017.01.004. Epub 2017 Mar 14.

11.

Characterization of the GNMT-HectH9-PREX2 tripartite relationship in the pathogenesis of hepatocellular carcinoma.

Li CH, Yen CH, Chen YF, Lee KJ, Fang CC, Zhang X, Lai CC, Huang SF, Lin HK, Arthur Chen YM.

Int J Cancer. 2017 May 15;140(10):2284-2297. doi: 10.1002/ijc.30652.

12.

A multidisciplinary team care approach improves outcomes in high-risk pediatric neuroblastoma patients.

Chang HH, Liu YL, Lu MY, Jou ST, Yang YL, Lin DT, Lin KH, Tzen KY, Yen RF, Lu CC, Liu CJ, Peng SS, Jeng YM, Huang SF, Lee H, Juan HF, Huang MC, Liao YF, Lee YL, Hsu WM.

Oncotarget. 2017 Jan 17;8(3):4360-4372. doi: 10.18632/oncotarget.13874.

13.

WITHDRAWN: Prognostic Significance of Programmed Cell Death-Ligand 1 Expression in Patients With Resected Lung Adenocarcinoma.

Hung JJ, Huang SF, Shen YY, Wu YC, Chou TY, Hsu WH.

Ann Thorac Surg. 2016 Oct 13. pii: S0003-4975(16)31027-X. doi: 10.1016/j.athoracsur.2016.07.074. [Epub ahead of print]

PMID:
27743638
14.

Selective Retention of an Inactive Allele of the DKK2 Tumor Suppressor Gene in Hepatocellular Carcinoma.

Lin YF, Li LH, Lin CH, Tsou MH, Chuang MT, Wu KM, Liao TL, Li JC, Wang WJ, Tomita A, Tomita B, Huang SF, Tsai SF.

PLoS Genet. 2016 May 20;12(5):e1006051. doi: 10.1371/journal.pgen.1006051. eCollection 2016 May.

15.

Expression levels of ROS1/ALK/c-MET and therapeutic efficacy of cetuximab plus chemotherapy in advanced biliary tract cancer.

Chiang NJ, Hsu C, Chen JS, Tsou HH, Shen YY, Chao Y, Chen MH, Yeh TS, Shan YS, Huang SF, Chen LT.

Sci Rep. 2016 May 3;6:25369. doi: 10.1038/srep25369.

16.

The Hepatitis Viral Status in Patients With Hepatocellular Carcinoma: a Study of 3843 Patients From Taiwan Liver Cancer Network.

Chang IC, Huang SF, Chen PJ, Chen CL, Chen CL, Wu CC, Tsai CC, Lee PH, Chen MF, Lee CM, Yu HC, Lo GH, Yeh CT, Hong CC, Eng HL, Wang J, Tseng HH, Hsiao CH, Wu HD, Yen TC, Liaw YF.

Medicine (Baltimore). 2016 Apr;95(15):e3284. doi: 10.1097/MD.0000000000003284.

17.

Diagnostic FDG and FDOPA positron emission tomography scans distinguish the genomic type and treatment outcome of neuroblastoma.

Liu YL, Lu MY, Chang HH, Lu CC, Lin DT, Jou ST, Yang YL, Lee YL, Huang SF, Jeng YM, Lee H, Miser JS, Lin KH, Liao YF, Hsu WM, Tzen KY.

Oncotarget. 2016 Apr 5;7(14):18774-86. doi: 10.18632/oncotarget.7933.

18.

Carboxypeptidase E is a prediction marker for tumor recurrence in early-stage hepatocellular carcinoma.

Huang SF, Wu HD, Chen YT, Murthy SR, Chiu YT, Chang Y, Chang IC, Yang X, Loh YP.

Tumour Biol. 2016 Jul;37(7):9745-53. doi: 10.1007/s13277-016-4814-7. Epub 2016 Jan 23.

PMID:
26803519
19.

Activated protein C attenuates ischemia-reperfusion-induced acute lung injury.

Lan CC, Peng CK, Huang SF, Huang KL, Wu CP.

Exp Lung Res. 2015 Jun;41(5):241-50. doi: 10.3109/01902148.2013.850125.

PMID:
26052825
20.

EGFR over-expression in non-small cell lung cancers harboring EGFR mutations is associated with marked down-regulation of CD82.

Yang CH, Chou HC, Fu YN, Yeh CL, Cheng HW, Chang IC, Liu KJ, Chang GC, Tsai TF, Tsai SF, Liu HP, Wu YC, Chen YT, Huang SF, Chen YR.

Biochim Biophys Acta. 2015 Jul;1852(7):1540-9. doi: 10.1016/j.bbadis.2015.04.020. Epub 2015 Apr 23.

Supplemental Content

Loading ...
Support Center